BREAST CANCER - WGD
1185 samples - 12.96 % of the cohort (P: 531 - 44.8 % | M: 654 - 55.2 %)
1182 samples with TP53 hits - 99.75 % (P: 530 - 44.8 % | M: 652 - 55.2 %)















NON-SMALL CELL LUNG CANCER - WGD
1533 samples - 16.76 % of the cohort (P: 772 - 50.4 % | M: 761 - 49.6 %)
1528 samples with TP53 hits - 99.67 % (P: 768 - 50.3 % | M: 760 - 49.7 %)















COLORECTAL CANCER - WGD
1097 samples - 11.99 % of the cohort (P: 637 - 58.1 % | M: 460 - 41.9 %)
1092 samples with TP53 hits - 99.54 % (P: 633 - 58.0 % | M: 459 - 42.0 %)

















GLIOMA - WGD
107 samples - 1.17 % of the cohort (P: 98 - 91.6 % | M: 9 - 8.4 %)
105 samples with TP53 hits - 98.13 % (P: 97 - 92.4 % | M: 8 - 7.6 %)















PROSTATE CANCER - WGD
229 samples - 2.5 % of the cohort (P: 66 - 28.8 % | M: 163 - 71.2 %)
222 samples with TP53 hits - 96.94 % (P: 64 - 28.8 % | M: 158 - 71.2 %)

















PANCREATIC CANCER - WGD
321 samples - 3.51 % of the cohort (P: 128 - 39.9 % | M: 193 - 60.1 %)
320 samples with TP53 hits - 99.69 % (P: 128 - 40.0 % | M: 192 - 60.0 %)















MELANOMA - WGD
259 samples - 2.83 % of the cohort (P: 51 - 19.7 % | M: 208 - 80.3 %)
259 samples with TP53 hits - 100.0 % (P: 51 - 19.7 % | M: 208 - 80.3 %)















ENDOMETRIAL CANCER - WGD
219 samples - 2.39 % of the cohort (P: 133 - 60.7 % | M: 86 - 39.3 %)
218 samples with TP53 hits - 99.54 % (P: 133 - 61.0 % | M: 85 - 39.0 %)















OVARIAN CANCER - WGD
482 samples - 5.27 % of the cohort (P: 185 - 38.4 % | M: 297 - 61.6 %)
482 samples with TP53 hits - 100.0 % (P: 185 - 38.4 % | M: 297 - 61.6 %)















SOFT TISSUE SARCOMA - WGD
239 samples - 2.61 % of the cohort (P: 144 - 60.3 % | M: 95 - 39.7 %)
238 samples with TP53 hits - 99.58 % (P: 143 - 60.1 % | M: 95 - 39.9 %)















BLADDER CANCER - WGD
296 samples - 3.24 % of the cohort (P: 223 - 75.3 % | M: 73 - 24.7 %)
294 samples with TP53 hits - 99.32 % (P: 222 - 75.5 % | M: 72 - 24.5 %)















CANCER OF UNKNOWN PRIMARY - WGD
279 samples - 3.05 % of the cohort (P: 29 - 10.4 % | M: 250 - 89.6 %)
279 samples with TP53 hits - 100.0 % (P: 29 - 10.4 % | M: 250 - 89.6 %)















HEPATOBILIARY CANCER - WGD
151 samples - 1.65 % of the cohort (P: 94 - 62.3 % | M: 57 - 37.7 %)
151 samples with TP53 hits - 100.0 % (P: 94 - 62.3 % | M: 57 - 37.7 %)















ESOPHAGOGASTRIC CANCER - WGD
308 samples - 3.37 % of the cohort (P: 212 - 68.8 % | M: 96 - 31.2 %)
308 samples with TP53 hits - 100.0 % (P: 212 - 68.8 % | M: 96 - 31.2 %)















RENAL CELL CARCINOMA - WGD
105 samples - 1.15 % of the cohort (P: 56 - 53.3 % | M: 49 - 46.7 %)
104 samples with TP53 hits - 99.05 % (P: 55 - 52.9 % | M: 49 - 47.1 %)















GERM CELL TUMOR - WGD
286 samples - 3.13 % of the cohort (P: 170 - 59.4 % | M: 116 - 40.6 %)
281 samples with TP53 hits - 98.25 % (P: 167 - 59.4 % | M: 114 - 40.6 %)















GASTROINTESTINAL STROMAL TUMOR - WGD
50 samples - 0.55 % of the cohort (P: 26 - 52.0 % | M: 24 - 48.0 %)
50 samples with TP53 hits - 100.0 % (P: 26 - 52.0 % | M: 24 - 48.0 %)

















THYROID CANCER - WGD
60 samples - 0.66 % of the cohort (P: 32 - 53.3 % | M: 28 - 46.7 %)
60 samples with TP53 hits - 100.0 % (P: 32 - 53.3 % | M: 28 - 46.7 %)

















HEAD AND NECK CANCER - WGD
79 samples - 0.86 % of the cohort (P: 40 - 50.6 % | M: 39 - 49.4 %)
78 samples with TP53 hits - 98.73 % (P: 39 - 50.0 % | M: 39 - 50.0 %)















NON-SMALL CELL LUNG CANCER - WGD
1533 samples - 16.76 % of the cohort (P: 772 - 50.4 % | M: 761 - 49.6 %)
1528 samples with TP53 hits - 99.67 % (P: 768 - 50.3 % | M: 760 - 49.7 %)















BONE CANCER - WGD
68 samples - 0.74 % of the cohort (P: 33 - 48.5 % | M: 35 - 51.5 %)
68 samples with TP53 hits - 100.0 % (P: 33 - 48.5 % | M: 35 - 51.5 %)















SKIN CANCER, NON-MELANOMA - WGD
39 samples - 0.43 % of the cohort (P: 15 - 38.5 % | M: 24 - 61.5 %)
39 samples with TP53 hits - 100.0 % (P: 15 - 38.5 % | M: 24 - 61.5 %)















MESOTHELIOMA - WGD
35 samples - 0.38 % of the cohort (P: 29 - 82.9 % | M: 6 - 17.1 %)
34 samples with TP53 hits - 97.14 % (P: 29 - 85.3 % | M: 5 - 14.7 %)















SALIVARY GLAND CANCER - WGD
45 samples - 0.49 % of the cohort (P: 16 - 35.6 % | M: 29 - 64.4 %)
45 samples with TP53 hits - 100.0 % (P: 16 - 35.6 % | M: 29 - 64.4 %)















UTERINE SARCOMA - WGD
47 samples - 0.51 % of the cohort (P: 26 - 55.3 % | M: 21 - 44.7 %)
47 samples with TP53 hits - 100.0 % (P: 26 - 55.3 % | M: 21 - 44.7 %)